1. A method of performing root cause identification for a failure on an integrated circuit with a logic built-in self-test (LBIST) system, the method comprising:
completing one or more cycles of test with the LBIST system, each of the one or more cycles enabling one or more macros associated with each of one or more channel scan paths;
identifying, using a processor, a failing cycle among the one or more cycles of test;
identifying a failing channel scan path among the one or more channel scan paths associated with the failing cycle;
identifying the one or more macros associated with the failing channel scan path; and
iteratively checking each of the one or more macros associated with the failing channel scan path to perform the root cause identification.
2. The method according to claim 1, wherein the enabling the one or more macros associated with each of the one or more channel scan paths includes executing logic on the one or more macros of each of the one or more channel scan paths with data from a pseudo-random pattern generator.
3. The method according to claim 1, wherein the identifying the failing cycle and the identifying the failing channel scan path includes comparing outputs of the one or more macros of each of the one or more channel scan paths, output to a multiple input signature register (MISR), with expected values.
4. The method according to claim 1, wherein the iteratively checking each of the one or more macros associated with the failing channel scan path includes applying a clock-off signal to all of the one or more macros associated with the failing channel scan path.
5. The method according to claim 4, wherein the iteratively checking each of the one or more macros associated with the failing channel scan path includes iteratively enabling one of the one or more macros associated with the failing channel scan path at each iteration.
6. The method according to claim 5, wherein the iteratively enabling one of the one or more macros associated with the failing channel scan path at each iteration includes executing the one of the one or more macros associated with the failing channel scan path enabled at each iteration to determine whether the failure is resolved or not resolved.
7. The method according to claim 6, further comprising identifying the one of the one or more macros associated with the failing channel scan path as a non-failing macro when the failure is resolved.
8. The method according to claim 6, further comprising identifying the one of the one or more macros associated with the failing channel scan path as a failing macro when the failure is not resolved.
9. The method according to claim 1, further comprising performing circuit analysis on each macro, of the one or more macros associated with the failing channel scan path, identified as a failing macro to identify one or more failing latches.
10-20. (canceled)
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An implantable medical device comprising:
a device body and a coating disposed over the device body, the coating comprising:
a drug reservoir layer comprising:
a peptide or protein;
a hydrophobic drug; and
a polymer with a weight average molecular weight between about 10 to about 150 K Daltons;
wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10;
wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;
wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days; and
wherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula:
wherein:
i is an integer from 1 to 10, inclusive;
j is an integer from 0 to 10, inclusive;
k is an integer from 0 to 15, inclusive;
xn is an integer from 0 to 100, inclusive;
ym is an integer from 0 to 150, inclusive;
p is an integer from 2 to about 4500;
Mw is from about 10,000 to about 1,000,000 Da;
si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;
si is a number from 0 to 0.5, inclusive;
tj is a number from 0 to 0.5, inclusive;
vk is a number from 0 to 0.5, inclusive;
with the proviso that
\u03a3isi+\u03a3jtj+\u03a3kvk=1.0;
\u03a3isi=\u03a3jtj+\u03a3kvk=0.5;
\u03a3isi>0;
\u03a3jtj>0 or \u03a3kvk>0;
each Ai has the chemical structure:
each Bj has the chemical structure
and
each Ck has the chemical structure:
wherein:
each Rbj, and Rbj\u2032 are independently selected from the group consisting of hydrogen and (C1-C4)alkyl, wherein:
the alkyl group is optionally substituted with a moiety selected from the group consisting of \u2014OH, \u2014SH, \u2014SeH, \u2014C(O)OH, \u2014NHC(NH)NH2,
phenyl and
or
one or more of Rbj and Rbj\u2032 may form a bridge between the carbon to which it is attached and the adjacent nitrogen, the bridge comprising \u2014CH2CH2CH2\u2014;
each Rai, and each Rcj are independently selected from the group consisting of (C1-C12)alkyl, (C2-C12)alkenyl, (C3-C8)cycloalkyl,-(CH2CH2O)CH2CH2\u2014 wherein q is an integer from 1 to 10, inclusive, and
where z is 0, 1, or 2;
subject to the restriction that at least one Rai is selected from the group consisting of
where z is 0, 1, or 2;
Rdk is selected from the group consisting of \u2014H, \u2014OH, \u2014O(C1-C20)alkyl, \u2014O(C1C20)alkenyl and \u2014O(CH 2CH2O)wCH2CH2ORek, wherein:
w is an integer from 1 to 600, inclusive;
Rek is selected from the group consisting of hydrogen,
\u2014C(O)CH\u2550CH2 and \u2014C(O)C(CH3)\u2550CH2; and,
each Rai, corresponds to the ith Ai group, each Rbj, Rbj\u2032 , and Rcj corresponds to the jth Bj group, and each Rdk and optionally Rek correspond to the kth Ck group.
2. The device of claim 1, wherein the implantable medical device is a stent.
3. The device of claim 1, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days.
4. The device of claim 1, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 10% and about 35% at 24 hours and between about 25% and about 75% at 7 days.
5. The device of claim 1, wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.2 to 1:5.
6. The device of claim 1, wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.5 to 1:3.
7. The device of claim 1, wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.2 to about 1:5.
8. The device of claim 1, wherein the mass ratio of the protein or peptide to the polymer is from about 1:2 to about 1:4.
9. An implantable medical device comprising:
a device body and a coating disposed over the device body, the coating comprising:
a drug reservoir layer comprising:
a peptide or protein;
a hydrophobic drug; and
a polymer with a weight average molecular weight between about 10 to about 150 K Daltons;
wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10;
wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;
wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days;
and
wherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula:
wherein:
i is an integer from 1 to 10, inclusive;
j is an integer from 0 to 10, inclusive;
k is an integer from 0 to 15, inclusive;
xn is an integer from 0 to 100, inclusive;
ym is an integer from 0 to 150, inclusive;
p is an integer from 2 to about 4500;
Mw is from about 10,000 to about 1,000,000 Da;
si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;
si is a number from 0 to 0.5, inclusive;
tj is a number from 0 to 0.5, inclusive;
vk is a number from 0 to 0.5, inclusive;
with the proviso that
\u03a3isi+\u03a3jtj+\u03a3kvk=1.0;
\u03a3isi=\u03a3jtj+\u03a3kvk=0.5;
\u03a3isi>0;
\u03a3jtj>0 or \u03a3kvk>0;
each Ai has the chemical structure:
each Bj has the chemical structure
and
each Ck has the chemical structure
each Rai corresponds to the ith Ai group, each Rbj, Rbj\u2032, and Rcj corresponds to the jth Bj group, and
each Rdk and optionally Rek correspond to the kth Ck group;
and
wherein i =1, j =2, k =0,
Ra1 is selected from the group consisting of \u2014(CH2)6\u2014, \u2014(CH2)7\u2014, \u2014(CH2)8\u2014, \u2014(CH2)9\u2014, and \u2014(CH2)10\u2014;
each of Rb1, Rb1\u2032, Rb2 and Rb2\u2032 are the same, and are selected from the group consisting of \u2014(CH2)\u2014,\u2014(CH(CH3)2) and \u2014(CH3);
Rc1 is selected from the group consisting of \u2014(CH2)4\u2014, \u2014(CH2)5\u2014, \u2014(CH2)6\u2014, \u2014(CH2)7\u2014, and \u2014(CH2)8\u2014;
and
Rc2 is selected from the group consisting of
where z is 0, 1, or 2.
10. The device of claim 9, wherein for the polymer
Ra1 is \u2014(CH2)8\u2014;
Rb1 Rb1\u2032 Rb2 and Rb2\u2032 the same and are \u2014(CH2)\u2014(CH(CH3)2) ;
Rc1 is \u2014(CH2)6\u2014;
Rc2 is
and
s1 is 0.5, and t1 is between 0.125 and 0.375.
11. The device of claim 9, wherein the peptide or protein is cRGD, and the hydrophobic drug is everolimus.
12. The device of claim 11, wherein the mass ratio of (protein or peptide):
hydrophobic drug: polymer is about 1:1:3.
13. The device of claim 1, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40- O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O- 2-hydroxy)ethoxyethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, \u03b3-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof.
14. The device of claim 13, wherein the hydrophobic drug is everolimus.
15. The device of claim 13, wherein the hydrophobic drug is zotarolimus.
16. The device of claim 1, wherein the hydrophobic drug is an anti-proliferative.
17. The device of claim 1, wherein the peptide or protein is selected from the group consisting of cRGD, other similar size peptides and combinations thereof.
18. The device of claim 1, wherein the peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, or a synthetic RGD mimetic and combinations thereof
19. The device of claim 18, wherein the peptide or protein is cRGD.
20. The device of claim 1, wherein the drug reservoir layer is between about 0.5 and about 9 \u03bcm in thickness.
21. The device of claim 1, wherein the mass ratio of (protein or peptide):
hydrophobic drug: polymer is about 1:1:3.
22. An implantable medical device comprising:
a device body and a coating disposed over the device body, the coating comprising;
a drug reservoir layer comprising:
a peptide or protein;
a hydrophobic drug;
a polymer with a weight average molecular weight between about 10 to about 150 K Daltons;
wherein the mass ratio of the peptide or protein to the hydrophobic drug is about 1:0.1 to about 1:10;
wherein the ratio of the sum of the mass of peptide or protein and the mass of the hydrophobic drug to the mass of the polymer is about 1:1 to about 1:12;
wherein the drug reservoir layer thickness is between about 0.5 and about 7 \u03bcm in thickness; and
wherein the polymer is poly(ester-amide) that is a random copolymer having the formula:
wherein:
A1 has the chemical structure:
each of B1 and B2 has the chemical structure
where j =1 for B1 and j =2 for B2;
s1, t1, and t2 represent the average mole fraction of each of A1, B1, and B2;
t1 is between 0.125 and 0.375;
t2 =0.5 \u2212t1;
s1 =0.5; and
p is an integer from 2 to about 4500;
wherein:
Ra1 is selected from the group consisting of \u2014(CH2)6\u2014, \u2014(CH2)7\u2014, \u2014(CH2)8\u2014,\u2014(CH2)9\u2014, and \u2014\u2014(CH2)10 \u2014;
each of Rb1 Rb1\u2032 , Rb2 and Rb2\u2032 are the same, and are selected from the group consisting of \u2014(CH2)\u2014(CH(CH3)2) and \u2014(CH3);
Rc1 is selected from the group consisting of \u2014(CH2)4\u2014,\u2014(CH2)5\u2014, \u2014(CH2)6\u2014,\u2014(CH2)7\u2014, and \u2014(CH2)8\u2014; and
Rc2 is selected from the group consisting of
where z is 0, 1, or 2.
23. The device of claim 22, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O-2-hydroxy)ethoxyethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, \u03b3-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof.
24. The device of claim 22, wherein the peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, a synthetic RGD mimetic, other similar size peptides, and combinations thereof.
25. A method of fabricating a coated implantable medical device comprising:
providing an implantable medical device;
providing a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons;
dissolving or dispersing the peptide or protein, the hydrophobic drug, and the polymer in ethanol wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10; and wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;
applying the ethanol solutiondispersion to the implantable medical device; and
removing the ethanol to form a drug reservoir layer;
wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days; and
wherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula:
wherein:
i is an integer from 1 to 10, inclusive;
j is an integer from 0 to 10, inclusive;
k is an integer from 0 to 15, inclusive;
xn is an integer from 0 to 100, inclusive;
ym is an integer from 0 to 150, inclusive;
p is an integer from 2 to about 4500;
Mw is from about 10,000 to about 1,000,000 Da;
s tj, and vk represent the average mole fraction of each of Al, Bj, and Ck;
si is a number from 0 to 0.5, inclusive;
tj is a number from 0 to 0.5, inclusive;
vk is a number from 0 to 0.5, inclusive;
with the proviso that
\u03a3isi+\u03a3jtj+\u03a3kvk=1.0;
\u03a3isi=\u03a3jtj+\u03a3kvk=0.5;
\u03a3isi>0;
\u03a3jtj>0 or \u03a3kvk>0;
each Ai, has the chemical structure:
each Bj has the chemical structure
and
each Ck has the chemical structure:
wherein:
each Rbj, and Rbj\u2032 are independently selected from the group consisting of hydrogen and (C1-C4)alkyl, wherein:
the alkyl group is optionally substituted with a moiety selected from the group consisting of \u2014OH, \u2014SH, \u2014SeH, \u2014C(O)OH, \u2014NHC(NH)NH2,
phenyl and
or
one or more of Rbj and Rbj\u2032 may form a bridge between the carbon to which it is attached and the adjacent nitrogen, the bridge comprising \u2014CH2CH2CH2-;
each Rai and each Rcj are independently selected from the group consisting of (C1-C12)alkyl, (C2-C12)alkenyl, (C3-C8)cycloalkyl,\u2014(CH2CH2O)qCH2CH2- wherein q is an integer from 1 to 10, inclusive, and
where z is 0, 1, or 2;
subject to the restriction that at least one Ra, is selected from the group consisting of
where z is 0, 1, or 2;
Rdk is selected from the group consisting of \u2014H, \u2014OH, \u2014O(C1-C20)alkyl, \u2014O(C1-C20)alkenyl and \u2014O(CH 2CH2O)wCH2CH2ORek, wherein:
w is an integer from 1 to 600, inclusive;
Rek is selected from the group consisting of hydrogen,
\u2014C(O)CH\u2550CH2 and \u2014C(O)C(CH3)\u2550CH2; and,
each Rai, corresponds to the ith Ai group, each Rbj, Rbj\u2032, and Rcj corresponds to the jth Bj group, and
each Rdk and optionally Rek correspond to the kth Ck group.
26. The method of claim 23, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days.
27. The method of claim 23, wherein the cumulative release of the hydrophobic drug from the drug reservoir layer is between 10% and about 35% at 24 hours and between about 25% and about 75% at 7 days.
28. A coated implantable medical device fabricated by the method of claim 25.
29. The device of claim 9, wherein Rc2 is selected from the group consisting of
30. The device of claim 9, wherein the hydrophobic drug is selected from the group consisting of sirolimus (rapamycin), biolimus A9, deforolimus, AP23572 (Ariad Pharmaceuticals), tacrolimus, temsirolimus, pimecrolimus, zotarolimus (ABT-578), 40- O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxypropyl)rapamycin, 40-O-2-(2-hydroxy)ethoxyethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-O-tetrazolylrapamycin, 40-epi-(N1-tetrazole)-rapamycin, paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), dexamethasone, \u03b3-hiridun, clobetasol, dexamethasone acetate, mometasone, imatinib mesylate, midostaurin, feno fibrate, feno fibric acid, and prodrugs thereof, co-drugs thereof, and combinations thereof;
and
the peptide or protein is selected from the group consisting of RGD, an RGD peptide, a cyclic RGD peptide (cRGD), a synthetic cyclic RGD (cRGD) mimetic, a synthetic RGD mimetic, other similar size peptides, and combinations thereof.
31. A method of fabricating a coated implantable medical device comprising:
providing an implantable medical device;
providing a peptide or protein, a hydrophobic drug, and a polymer with a weight average molecular weight between about 10,000 to about 150,000 Daltons;
dissolving or dispersing the peptide or protein, the hydrophobic drug, and the polymer in ethanol wherein the mass ratio of the peptide or protein to the hydrophobic drug is from about 1:0.1 to about 1:10; and wherein the mass ratio of the protein or peptide to the polymer is from about 1:0.1 to about 1:10;
applying the ethanol solutiondispersion to the implantable medical device; and
removing the ethanol to form a drug reservoir layer;
wherein the cumulative release of the peptide or protein from the drug reservoir layer is between about 5% and about 50% at 24 hours and between about 10% and about 95% at 7 days;
and
wherein the polymer is a poly(ester-amide) or a poly(amide) that is of the following formula:
wherein:
si, tj, and vk represent the average mole fraction of each of Ai, Bj, and Ck;
i is an integer from 1 to 10, inclusive;
j is an integer from 0 to 10, inclusive;
k is an integer from 0 to 15, inclusive;
xn is an integer from 0 to 100, inclusive;
ym is an integer from 0 to 150, inclusive;
p is an integer from 2 to about 4500;
Mw is from about 10,000 to about 1,000,000 Da;
si is a number from 0 to 0.5, inclusive;
tj is a number from 0 to 0.5, inclusive;
vk is a number from 0 to 0.5, inclusive;
with the proviso that
\u03a3isi+\u03a3jtj+\u03a3kvk=1.0;
\u03a3isi=\u03a3jtj+\u03a3kvk=0.5;
\u03a3isi>0;
\u03a3jtj>0 or \u03a3kvk>0;
each A, has the chemical structure:
each Bj has the chemical structure
and
each Ck has the chemical structure:
each Rai corresponds to the ith Ai group, each Rbj, Rbj\u2032, and Rcj corresponds to the jth Bj group, and
each Rdk and optionally Rek correspond to the kth Ck group; and
wherein i=1, j=2, k=0,
Ra1 is selected from the group consisting of \u2014(CH2)6\u2014, \u2014(CH2)7\u2014, \u2014(CH2)8\u2014, \u2014(CH2)9\u2014, and (CH2)10\u2014;
each of Rb1, Rb1\u2032, Rb2 and Rb2\u2032 are the same, and are selected from the group consisting of \u2014(CH2)\u2014(CH(CH3)2) and \u2014(CH3);
Rc1 is selected from the group consisting of \u2014(CH2)4\u2014, \u2014(CH2)5\u2014, (CH2)6\u2014, \u2014(CH2)7\u2014, and \u2014(CH2)8\u2014; and
Rc2 is selected from the group consisting of
where z is 0, 1, or 2.
32. A coated implantable medical device fabricated by the method of claim 31.